Senior Consulting Fellow, Centre on Global Health Security
Charles Clift
Contact information
+44 20 7731 4792

Summary

Charles Clift is a senior consulting fellow at the Centre on Global Health Security at Chatham House. He is also chair of the Medicines Patent Pool, a Swiss charitable foundation seeking to increase access to medicine for people living with HIV in developing countries. For a large part of his career he worked as an economist in the UK Department for International Development with experience of working in Kenya, India and the Caribbean. From 2004 to 2006 he was a staff member of the World Health Organization (WHO). In addition to his work for Chatham House, he has been a consultant to the WHO, UNITAID, the World Intellectual Property Organization and the Access to Medicine Foundation. His research interests at Chatham House include counterfeit medicines, global health governance and financing, and antimicrobial resistance. He has a BA from The University of Cambridge and an MA and PhD from The University of Sussex.

Expertise

  • Access to medicines in developing countries
  • Counterfeit medicines
  • Intellectual property, innovation and public health
  • Health economics/financing

Experience

2010 -Independent consultant
2007 - 09Senior Adviser, Access to Medicines, Department for International Development, UK
2004 - 06Secretary, Commission on Intellectual Property Rights, Innovation and Public Health, World Health Organization
2001 - 03Secretary, UK Commission on Intellectual Property Rights
Up to 2001Economic Adviser in UK Department for International Development
  • The Role of the World Health Organization in the International System Working Group Paper, February 2013
  • Is Universal Health Coverage Good for Health? Universal Health Coverage and the Post-2015 Development Agenda The World We Want, January 2013
  • Counterfeit Medicines: Health and Harm The World Today, December 2010
  • Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way Forward? Chatham House Briefing Paper, 2010
  • Why IPR issues were brought to GATT? A historical perspective on the origins of TRIPS, in C. Correa (ed.) Research Handbook On The Protection Of Intellectual Property Under WTO Rules, Elgar, 2010
  • The value of patent term extensions to the pharmaceutical industry in the USA, Journal of Generic Medicines, 2008
  • A Guide to Assessing the Impact of TRIPS-Plus Provisions on Drug Prices in Developing Countries, International Centre for Trade and Sustainable Development, Geneva, 2007
  • Patenting and Licensing Research Tools in Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, (eds. A Krattiger, RT Mahoney, L Nelsen, et al) MIHR, Oxford, 2007
  • Data Protection and Data Exclusivity in Pharmaceuticals and Agrochemicals, in Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al) MIHR, Oxford, 2007
  • Traditional knowledge and modern science: Is intellectual property protection a good idea? in P. Sillitoe (ed.), Local Science vs Global Science: Approaches to Indigenous Knowledge in International Development, Berghahn Books, 2006
  • Public health, innovation and intellectual property rights: unfinished business, Bulletin of the World Health Organization, Vol.84, 338, 2006